Shares of Anacor Pharmaceuticals jumped 26% one day, and 30% the next, with an even bigger catalyst on the horizon. What is driving these explosive share price surges? In the video below, Fool analyst David Williamson discusses one phase 2 trial that has the markets excited, and tells us why the results from its upcoming phase 3 trial for this candidate pipeline drug could be even bigger.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Anacor Cannot Be Contained originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.